Proteus launches its first digital cancer chemotherapy pill by Conor Hale Thursday, January 17, 2019 Proteus Digital Health launched a smart chemotherapy pill that aims to help oncologists track effectiveness and adherence in their cancer patients.
CellMax Life blood test spots 90% of colorectal polyps in study by Conor Hale Monday, January 14, 2019 CellMax Life was able to detect the small, precancerous colon polyps known as adenomas with close to 90% accuracy using a blood-based test.
AstraZeneca’s tremelimumab fails another phase 3 cancer trial by Nick Paul Taylor Friday, December 7, 2018 Having failed to improve outcomes in metastatic NSCLC, the anti-CTLA4 antibody has now missed the mark in a phase 3 head and neck cancer trial.
New discoveries in hematology and epilepsy—News of Note by Arlene Weintraub Monday, December 3, 2018 The week’s news included antibodies that lower the risks of bone marrow transplants and a new way to target a mutation in epilepsy.
Boehringer powers cancer vaccine startup Amal to B round by Nick Paul Taylor Monday, November 12, 2018 Boehringer Ingelheim Venture Fund co-led the financing to tee Amal up to take lead colorectal cancer vaccine ATP128 into the clinic next year.
Exact Sciences ups forecasts with 241,000 Cologuard tests in Q3 by Conor Hale Wednesday, October 31, 2018 Exact Sciences announced third-quarter revenues of $118.3 million after it screened about 241,000 people with its Cologuard at-home test.
Insight into KRAS mutations may aid cancer drug development by Angus Liu Thursday, September 13, 2018 Different KRAS mutations exert diverging effects on protein function, a new study illustrates.
Gritstone Oncology files for $80M IPO by Amirah Al Idrus Thursday, August 23, 2018 After raising more than $194 million in venture capital, Gritstone is looking to raise up to $80 million in its IPO.
Pfizer sales reps to co-promote Exact Sciences’ Cologuard test by Conor Hale Wednesday, August 22, 2018 Pfizer signed on to co-promote Exact Sciences’ Cologuard colorectal cancer screening test, committing to about $70 million on marketing through 2021.
AstraZeneca drops Amgen-partnered solid tumor drug by Nick Paul Taylor Friday, May 18, 2018 The CEA-CD3 bispecific T-cell engager was pitched as a treatment for colorectal cancer but looks to have failed in early-phase trials.